Angela Thedinga
Direktor/Vorstandsmitglied bei NKARTA, INC.
Vermögen: - $ am 31.05.2024
Profil
Angela M.
Thedinga is currently an Independent Director at Nkarta, Inc. She previously served as the Chief Technology Officer at Adverum Biotechnologies, Inc. from 2019 to 2021 and as the Chief of Staff & VP-Program Management at Novartis Gene Therapies, Inc. from 2018 to 2019.
Ms. Thedinga holds a graduate degree from the Massachusetts Institute of Technology, an undergraduate degree from the University of Wisconsin, a graduate degree from The University of North Carolina at Chapel Hill, and an MBA from MIT Sloan School of Management.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NKARTA, INC.
-.--% | 13.06.2024 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von Angela Thedinga
| Unternehmen | Position | Beginn |
|---|---|---|
| NKARTA, INC. | Direktor/Vorstandsmitglied | 28.03.2022 |
Ehemalige bekannte Positionen von Angela Thedinga
| Unternehmen | Position | Ende |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2021 |
| AVEXIS INC | Personalreferent | 01.06.2019 |
Ausbildung von Angela Thedinga
| Massachusetts Institute of Technology | Graduate Degree |
| MIT Sloan School of Management | Masters Business Admin |
| The University of North Carolina at Chapel Hill | Graduate Degree |
| University of Wisconsin | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| NKARTA, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
